Rudolph, CA
Aaron Rudolph, San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20130015964 | MOTOR VEHICLEAANM MULLER; UlrichAACI IngolstadtAACO DEAAGP MULLER; Ulrich Ingolstadt DEAANM RUDOLPH; AaronAACI San FranciscoAAST CAAACO USAAGP RUDOLPH; Aaron San Francisco CA USAANM KUHNE; MarcusAACI IngolstadtAACO DEAAGP KUHNE; Marcus Ingolstadt DE - The invention relates to a motor vehicle which includes a display for presenting a list of entries, wherein an entry has an associated function of the motor vehicle, and wherein the motor vehicle comprises a rotary knob which is associated with the display, which can be rotated about an axis of rotation and which can be rotated through a prescribed angle of rotation in order to move a marker from one entry to an entry which is adjacent thereto. | 01-17-2013 |
Aaron Rudolph, Montara, CA US
Patent application number | Description | Published |
---|---|---|
20140257567 | SLIDING HARD KEYS - A console includes a display and a plurality of individually-actuatable modules, including a physical key configured to slide into and out of a surface of the console. The modules include a motor, a threaded shaft coupled to and extending from the motor, and a movable platform movably attached to the threaded shaft. The physical key is movably supported on the movable platform. | 09-11-2014 |
20140267041 | TRACKBALL INPUT DEVICE WITH ADDITIONAL ROCKING MOTION - A system includes a graphical user interface and a trackball device configured to provide controlling input to the graphical user interface. The trackball device includes a trackball configured to allow a rocking motion along an axis of the trackball. | 09-18-2014 |
Aaron Rudolph, Montana, CA US
Patent application number | Description | Published |
---|---|---|
20140001834 | USER INTERFACE OF A VEHICLE | 01-02-2014 |
Alfred Rudolph, Los Altos Hills, CA US
Patent application number | Description | Published |
---|---|---|
20100221274 | METHOD OF ADMINISTERING A THYMOSIN ALPHA 1 PEPTIDE - A Thymosin alpha 1 (TA1) peptide is administered to a patient in need of immune stimulation so as to substantially continuously maintain an immune stimulating-effective amount of the TA1 peptide in the patient. The administration method may be by continuous infusion. | 09-02-2010 |
Alfred R. Rudolph, Los Altos Hills, CA US
Patent application number | Description | Published |
---|---|---|
20090074815 | Immunomodulator Compounds as Vaccine Enhancers - A vaccination method utilizes a pharmaceutical combination for enhancing vaccine effectiveness. The method utilizes an immune response-triggering vaccine capable of stimulating production in an immunodefficicent animal of antibodies to a disease-causing agent foreign to the animal. As an adjuvant, a vaccine effectiveness-enhancing amount of an immunomodulator compound is administered, which enhances production and affinity of the antibodies in the animal, in response to the vaccine. | 03-19-2009 |
20090088392 | TREATMENT OF MELANOMA - An immunomodulatory compound is administered to treat, prevent, inhibit, or reduce melanoma in a subject. | 04-02-2009 |
20090143313 | Treatment or Prevention of Hemorrhagic Viral Infections with Immunomodulator Compounds - An immunomodulatory compound is administered to a patient having, or at risk of a hemorrhagic viral infection. | 06-04-2009 |
20100092499 | Alpha Thymosin Peptides as Cancer Vaccine Adjuvants - A pharmaceutical combination and method for enhancing cancer vaccine effectiveness in a subject, utilize an immune response-triggering cancer vaccine capable of eliciting an immune system response in a subject; and a vaccine effectiveness-enhancing amount of an alpha thymosin peptide, which enhances the immune system response in the subject, wherein the cancer vaccine and the alpha thymosin peptide can be administered separately or together. | 04-15-2010 |
Arthur Rudolph, San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20150186667 | AGGREGATED ACTIONS - Exemplary methods, apparatuses, and systems receive a first plurality of actions from a first entity with respect to a first plurality of objects. A global object related to each of the first plurality of objects is determined and a representation of the global object is displayed in association with a representation of the first entity. Additionally, in response to receiving user feedback on the representation of the global object displayed in association with the representation of the first entity, an instance of the global object that is unique to the first entity is created. The displayed representation of the global object is converted into a representation of the instance of the global object that is unique to the first entity. | 07-02-2015 |
Arthur George Rudolph, San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20160050287 | MANAGING ACCESS TO USER INFORMATION BY APPLICATIONS OPERATING IN AN ONLINE SYSTEM ENVIRONMENT - An online system regulates access to information about a user by associating an online system user identifier with a unique application-specific user identifier used by an application to identify the user. Each application communicating with the online system and installed by the user is associated with a unique application-specific user identifier that is associated with the user's online system user identifier. For example, information identifying an installed application and an application-specific user identifier are associated with the user's online system user identifier when the user installs the application. When communicating about a user with an installed application associated with the user, the online system identifies the user via the application-specific identifier associated with the installed application and may provide limited information associated with the online system user identifier associated with the application-specific identifier. | 02-18-2016 |
Arthur George Rudolph, San Fracisco, CA US
Patent application number | Description | Published |
---|---|---|
20130073979 | TOOL FOR CREATING STRUCTURED OBJECTS AND ACTIONS ON A SOCIAL NETWORKING SYSTEM - A social networking system includes a mechanism for integrating user actions on objects outside of the social networking system in the social graph. External system operators include widgets that, when executed by user devices, record user interactions that correspond to a defined structure of actions and objects. Third party operators utilize a tool provided by the social networking system to define the structure of actions and objects. External actions are recorded by the social networking system for publishing to the social graph. | 03-21-2013 |
Authur Geogre Rudolph, San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20130073983 | INTEGRATING STRUCTURED OBJECTS AND ACTIONS GENERATED ON EXTERNAL SYSTEMS INTO A SOCIAL NETWORKING SYSTEM - A social networking system includes a mechanism for integrating user actions on objects outside of the social networking system in the social graph. For example, streaming music on external systems may be integrated into the user experience on the social networking system. Third-party developers, in addition to administrators of the social networking system, may define objects and actions that enable integration of external music sources to be played and controlled using the social networking system while also providing socially relevant information to other users of the social networking system. Actions and objects recorded from these external user interactions are structured to enable aggregation and structured querying, which enables data visualizations of the information discoverable on the social graph. In this way, interesting information about users' actions outside of the domain of the social networking system may be shared and compared with other users on the social networking system. | 03-21-2013 |
Colin Rudolph, San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20140170259 | NUTRITIONAL COMPOSITION FOR PROMOTING SATIETY - Provided herein are nutritional compositions comprising a protein source, a fat source, a carbohydrate source, and at least one nucleotide, wherein the protein source comprises at least one free amino acid, wherein the at least one free amino acid comprises a glutamate salt, glutamic acid, taurine, glutamine, alanine, or any combination thereof. Also provided herein are methods of promoting satiety, preventing or reducing the incidence of overweight or obesity, or preventing or reducing the incidence of diabetes in a subject comprising administering to a subject a nutritional composition comprising a protein source, a fat source, a carbohydrate source, and at least one nucleotide, wherein the protein source comprises at least one free amino acid, wherein the at least one free amino acid comprises a glutamate salt, glutamic acid, taurine, glutamine, alanine, or any combination thereof. | 06-19-2014 |
20150290260 | METHODS OF USE FOR PROBIOTICS AND PREBIOTICS - The present disclosure relates to method(s) for reducing the risk of visceral pain hypersensitivity, modulating the gut-brain axis, or reducing the local inflammatory response in a subject. The method(s) include providing a nutritional composition that includes | 10-15-2015 |
20150290261 | METHODS OF USE FOR PROBIOTICS AND PREBIOTICS - The present disclosure relates to method(s) for reducing the risk of visceral pain hypersensitivity, modulating the gut-brain axis, or reducing the local inflammatory response in a subject. The method(s) include providing a nutritional composition that includes | 10-15-2015 |
Dale A. Rudolph, San Diego, CA US
Patent application number | Description | Published |
---|---|---|
20080306085 | NON-IMIDAZOLE ARYLOXYALKYLAMINES - Substituted aryloxyalkylamines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions. | 12-11-2008 |
20090263322 | OCTAHYDRO-INDOLIZINE AND QUINOLIZINE AND HEXAHYDRO-PYRROLIZINES - The invention features substituted fused bicyclic compounds, pharmaceutical compositions containing them, and methods of using them to treat or prevent histamine-mediated diseases and conditions. | 10-22-2009 |
20090270370 | FUSED HETEROCYCLIC COMPOUNDS - Certain fused pyrrole- and pyrazole-containing heterocyclic compounds are serotonin modulators useful in the treatment of serotonin-mediated diseases. | 10-29-2009 |
20100004241 | NON-IMIDAZOLE ARYLOXYALKYLAMINES - Substituted aryloxyalkylamines of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions. | 01-07-2010 |
20100016281 | PYRIMIDINE COMPOUNDS AS SEROTONIN RECEPTOR MODULATORS - Certain pyrimidine-containing compounds are serotonin receptor modulators useful in the treatment of serotonin-mediated diseases. | 01-21-2010 |
20110040088 | FUSED HETEROCYCLIC COMPOUNDS - Certain fused pyrrole- and pyrazole-containing heterocyclic compounds are serotonin modulators useful in the treatment of serotonin-mediated diseases. | 02-17-2011 |
20120015957 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR - The present invention is directed to piperidinyl and piperazinyl derivatives of formula (I) useful as inhibitors of the NPY Y2 receptor, pharmaceutical compositions comprising said compounds, processes for the preparation of said compounds and the use of said compounds for the treatment and/or prevention of disorders, diseases and conditions mediated by the NPY Y2 receptor. | 01-19-2012 |
20120129870 | PIPERAZINYL DERIVATIVES USEFUL AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR - The present invention is directed to piperidinyl and piperazinyl derivatives of formula (II) useful as inhibitors of the NPY Y2 receptor, pharmaceutical compositions comprising said compounds, processes for the preparation of said compounds and the use of said compounds for the treatment and/or prevention of disorders, diseases and conditions mediated by the NPY Y2 receptor. | 05-24-2012 |
20120202783 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS - Disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo[3.2.0]heptane compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia. | 08-09-2012 |
20120208812 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS - Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia. | 08-16-2012 |
20130137672 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS - Certain disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo[3.2.0]heptane are described, which are useful as orexin inhibitors. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia. | 05-30-2013 |
20140179697 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS - Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia. | 06-26-2014 |
20140275056 | P2X7 MODULATORS - The present invention is directed to a compound of Formula (I): | 09-18-2014 |
20140275120 | P2X7 MODULATORS - The present invention is directed to a compound of Formula (I) | 09-18-2014 |
20150335651 | DISUBSTITUTED OCTAHYDROPYRROLO[3,4-c]PYRROLES AS OREXIN RECEPTOR MODULATORS - Disubstituted octahydropyrrolo[3,4-c]pyrrole compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia. | 11-26-2015 |
20160024082 | P2X7 MODULATORS - The present invention is directed to a compound of Formula (I) or (Ia) The invention also relates to pharmaceutical compositions comprising compounds of Formula (I) or (Ia) and methods comprising administering of compounds of Formula (I) or (Ia) for treating rheumatoid arthritis, osteoarthritis, psoriasis, septic shock, allergic dermatitis, asthma, allergic asthma, mild to severe asthma, steroid resistant asthma, idiopathic pulmonary fibrosis, allergic rhinitis, chronic obstructive pulmonary disease; airway hyper-responsiveness, diseases of the nervous and neuro-immune system, acute and chronic pain states of neuropathic pain, inflammatory pain, spontaneous pain, opioid induced pain, diabetic neuropathy, postherpetic neuralgia, low back pain, chemotherapy-induced neuropathic pain, fibromyalgia, diseases involved with and without neuroinflammation of the central nervous system, mood disorders, major depression, major depressive disorder, treatment resistant depression, bipolar disorder, anxious depression, anxiety, cognition, sleep disorders, multiple sclerosis, epileptic seizures, Parkinson's disease, schizophrenia, Alzheimer's disease, Huntington's disease, autism, spinal cord injury and cerebral ischemia/traumatic brain injury, stress-related disorders, diseases of the cardiovascular, metabolic, gastrointestinal and urogenital systems such as diabetes, diabetes mellitus, thrombosis, irritable bowel syndrome, irritable bowel disease, Crohn's disease, ischemic heart disease, ischaemia, hypertension, cardiovascular disease, myocardial infarction, and lower urinary tract dysfunction such as incontinence, lower urinary tract syndrome, Polycystic Kidney Disease, Glomerulonephritis, skeletal disorders, osteoporosis, osteopetrosis, and glaucoma, interstitial cystitis, cough, ureteric obstruction, sepsis, Amyotrophic Lateral Sclerosis, Chaga's Disease, | 01-28-2016 |
20160039836 | P2X7 MODULATORS - The present invention is directed to a compound of Formula (I): wherein: The present invention is directed to a compound of Formula (I): wherein: n is an integer from 0-1; X is CH2 when n is 0, or X is CH2 or oxygen when n is 1; R | 02-11-2016 |
Joachim Rudolph, South San Fransisco, CA US
Patent application number | Description | Published |
---|---|---|
20110110889 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 05-12-2011 |
Joachim Rudolph, South San Francisco, CA US
Patent application number | Description | Published |
---|---|---|
20110092479 | PYRAZOLE [3, 4-B] PYRIDINE RAF INHIBITORS - Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 04-21-2011 |
20120157439 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 06-21-2012 |
20120157451 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds of Formula (I) are useful for inhibition of Raf kinases. Methods of using compounds of Formula (I) and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 06-21-2012 |
20120157453 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds of Formula II are useful for inhibition of Raf kinases. Methods of using compounds of Formula II and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 06-21-2012 |
20120214811 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 08-23-2012 |
20130018033 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF - Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. | 01-17-2013 |
Joachim Rudolph, Burlingame, CA US
Patent application number | Description | Published |
---|---|---|
20090082328 | Substituted phenylamino-benzene derivatives useful for treating hyper-proliferative disorders and diseases associated with mitogen extracellular kinase activity - This invention relates to novel substituted phenylamino-benzene compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients. | 03-26-2009 |
20090209451 | HETEROARYLAMINOPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES - The present invention relates to heteroarylaminopyrazole compounds, pharmaceutical compositions, and methods for treating diabetes and related disorders. | 08-20-2009 |
20110071125 | SUBSTITUTED PHENYLAMINO-BENZENE DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH MITOGEN EXTRACELLULAR KINASE ACTIVITY - This invention relates to novel substituted phenylamino-benzene compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for treating hyper-proliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients. | 03-24-2011 |
20130178486 | SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula I wherein A, R | 07-11-2013 |
20130225620 | SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula I wherein A, Z, R | 08-29-2013 |
20140323477 | SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula I, or a pharmaceutically acceptable salt thereof, wherein R | 10-30-2014 |
20140323478 | SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula I, or a pharmaceutically acceptable salt thereof, wherein R | 10-30-2014 |
20150031674 | SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula I wherein R | 01-29-2015 |
Michael J. Rudolph, Irvine, CA US
Patent application number | Description | Published |
---|---|---|
20080256012 | DYNAMICALLY GENERATING AND DELIVERING INFORMATION IN RESPONSE TO THE OCCURRENCE OF AN EVENT - A facility for generating information in response to the occurrence of events is described. The facility detects the occurrence of one of a plurality of defined events. The facility matches the detected event occurrence against a set of scenarios. Each scenario specifies one or more matching rules, content, and a set of recipients. The facility aggregates the content specified by the subset of the set of scenarios whose matching rules are satisfied by the event occurrence for the recipients specified by this subset of scenarios. | 10-16-2008 |
Michael K. Rudolph, Belmont, CA US
Patent application number | Description | Published |
---|---|---|
20080281904 | Associating service listings with open source projects - Embodiments of a service listing system for open source software projects are described. A plurality of available open source projects are stored in a centralized or distributed database system. Each open source project comprises one or more software programs. Third party support and maintenance services may be provided by third parties service providers. The service listing system associates one or more service listings from service providers with appropriate open source projects. The service listing includes contact information for the service provider, and a schedule of provided services and products, and fees, if applicable. Service listings can be associated with projects based on a specific identification of projects or a definition of categories or types of projects. The system includes an integrated search engine that allows project users to find services based on specific projects or specific services that are available. A rating and certification system allows users to rate service providers and provide feedback that can be used by other potential users of the service provider. | 11-13-2008 |